MedTrace Logo

Photochemical Tissue Passivation Treatment of Saphenous Vein Grafts in CABG

NCT06150872 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2024-10-21

No results posted yet for this study

Summary

Early feasibility study of the DurVena Photochemical Tissue Passivation (PTP) device for treatment of saphenous vein grafts in participants undergoing elective coronary artery bypass graft (CABG) surgery. Study to be conducted outside the U.S.

Conditions

Interventions

DEVICE

DurVena Photochemical Tissue Passivation

Treatment of a saphenous vein graft with the DurVena Photochemical Tissue Passivation device.

Sponsors & Collaborators

  • DurVena, Inc.

    lead INDUSTRY

Principal Investigators

  • Abdusalom Abdurakhmanov, MD · Republican Scientific Center of Emergency Medical Care, Uzbekistan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-08
Primary Completion
2025-01-30
Completion
2025-03-30
FDA Device
Yes

Countries

  • Uzbekistan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06150872 on ClinicalTrials.gov